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ABSTRACT
Objective: This study aims to develop a function for mapping the English
and Chinese versions of the Functional Assessment of Cancer Therapy–
General (FACT–G) scores to the EuroQoLGroup’s EQ-5Dutility index and
to test whether a single function is sufﬁcient for the two language versions.
Methods: A baseline survey of 558 cancer patients in Singapore using the
FACT–G and EQ-5D was conducted (308 English and 250 Chinese ques-
tionnaires). Regression models were used to predict the EQ-5D utility
index values based on the FACT–G scores and thus derive a mapping
equation. Data from a follow-up survey of the patients were used to
validate the results.
Results: The FACT–G Social/Family scale was not associated with the
EQ-5D utility index (P = 0.701). There was no interaction between
language version and the predictors (each P > 0.1). An equation that maps
the FACT–G Physical, Emotional, and Functional well-being scales to the
EQ-5D utility index was derived. In the validation sample, the mean
observed utility values was larger than the mapped by only 0.005 (95%
conﬁdence interval [CI] -0.006 to 0.016), but the mean absolute difference
was 0.083 (95% CI 0.076 to 0.090).
Conclusions: At the group level, but not individual level, the equation
developed can accurately map the English and Chinese versions of the
FACT–G scores to the EQ-5D utility index.
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Introduction
Most cancer-speciﬁc quality-of-life instruments currently avail-
able are based on “psychometric” or “clinometric” principles
[1,2]. They were not developed for quantiﬁcation of the value
of a health status or quality-adjusted survival time [3]. The
Functional Assessment of Cancer Therapy–General (FACT–G)
has been widely used in a variety of cancer clinics and in many
parts of the world [4]. Like many other instruments, the
FACT–G is an ordinal-level measurement scale: A higher value
represents a better quality of life, but the difference between
two values cannot be interpreted quantitatively. For example,
the difference between the options of “somewhat” and “a little
bit” are not the same as the difference between options “a little
bit” and “not at all.” In contrast, for an interval-level measure-
ment scale, the difference in scores 0.3 and 0.4 is the same as
the difference in scores 0.4 and 0.5. A utility value is one such
quantitative, interval-level measure that is often needed in cost-
utility and quality-adjusted life-year analyses. The EuroQol
Group’s 5-domain questionnaire, EQ-5D, is a preference-based
health-related quality of life (HRQoL) measure which has been
tested and used in several disease groups [2]. As opposed to the
FACT–G or other ordinal-level measurement scales, the EQ-5D
explicitly takes into account the respondents’ preferences (or
trade-off) between various health states and generates the utility
values accordingly. Value sets and algorithms have been devel-
oped for transforming the descriptors into a single utility index
that has a value not larger than one, where one represents full
health [5,6].
Several noncancer studies have attempted to map HRQoL
measures to preference-based utility indices by regression
methods, so that the application of one HRQoL measure can
achieve the dual purpose of qualitative description of patients’
situation and quantiﬁcation of the utility of patients’ health
status and survival time [7–10]. The accuracy of mapping can be
assessed by using a data set to develop a mapping function, and
then applying the mapping function to another data set and
comparing the predicted and observed values. A recent study
mapped the FACT–Prostate to the EQ-5D utility index [11], but
the mean absolute deviation (about 0.15) was substantially larger
than what is usually considered a minimal clinically signiﬁcant
difference. This suggests that the mapping was not accurate at the
individual level. Alternatively, Kind andMacran [12] and Lamers
et al. [13] elicited preference weights for the FACT–Lung health
states using visual analog scale (VAS) as the preference measure.
The validity of the methodology used has been debated [14,15].
A study of the FACT–G directly elicited time trade-off utility
values in a sample of cancer patients and developed an equation
for using the FACT–G items to calculate a utility index [16]. The
weighting represents patients’ preferences although it is generally
recommended that economic evaluation should be based on soci-
etal preferences [16]. Most of these studies used the English
version of the HRQoL instruments; none of them used an Asian
language version. In 1995, about 7% and 20% of the world’s
population used English and Chinese, respectively, as their
primary languages [17].
This study aims to map the FACT–G to the EQ-5D utility
index in cancer patients in Singapore, so that clinicians and
researchers can obtain both a psychometric description and a
quantitative utility summary of a patient’s HRQoL from a single
assessment using FACT–G. This has the potential of facilitating
pharmacoeconomic and other quantitative evaluations without
imposing additional assessment burden on patients. Both the
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FACT–G and EQ-5D have a Chinese version, and previous
studies have suggested that the two language versions of
the FACT–G and EQ-5D achieve measurement equivalence
[18,19,20]. We have assessed whether a single mapping function
can be used for both language versions.
Methods
Design and Recruitment
This is part of a larger study that aimed to conﬁrm the measure-
ment properties of the English and Chinese versions of the
EQ-5D in cancer patients [20]. The study was approved by the
Ethics Committee of the National Cancer Centre, Singapore.
Outpatients who attended the Centre during the period between
September 2004 and July 2006 were invited to participate. The
patients were approached by a research coordinator while they
were in the waiting areas of the specialist outpatient clinics, the
ambulatory treatment unit, or the therapeutic radiology depart-
ment. The inclusion criteria were broad: aged 18 years or older,
ability to give written informed consent, and ability to under-
stand Chinese or English. Patients who fulﬁlled the inclusion
criteria and provided written informed consent chose to answer
either a Chinese or an English questionnaire package according
to their language preference. The packages included the EQ-5D
and the FACT–G, as well as questions on demographic charac-
teristics, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, and other clinical characteristics. Consented
participants were asked to self-administer and return the ques-
tionnaires during the same visit. The participants were sent a
similar questionnaire package by post in the same language with
postage-paid return envelope enclosed approximately 7 days
after the baseline interview. Up to two reminders with the ques-
tionnaires would be sent at 2-weekly intervals if the question-
naires were not returned.
For the present part of the study, only ethnic Chinese patients,
the ethnic majority in Singapore, were included in the analysis.
The number of participants from the other ethnic groups was
small and the inclusion of the minority ethnic groups would
make the test of interaction between language versions (Chinese
or English) and predictors uninterpretable. Participants who
requested proxy response or interviewer administration were
also excluded from the analysis.
Instruments and Variables
The 27-item FACT–G version 4 was used. The FACT–G consists
of four domain scales: Physical (GP), Social/Family (GS), Emo-
tional (GE), and Functional (GF) well-being. The validity and
reliability of both the English and Chinese versions of the
FACT–G as well as their measurement equivalence had been
assessed in Singapore in previous studies [19,21]. The ﬁve
ordinal-level responses to each item were coded as 0, 1, 2, 3, or
4 in such a way that a higher score indicated a better quality of
life. The standard “half-rule” was used to impute missing item
scores. The total and domain scales are obtained by summing the
responses to the individual items they comprise.
A Singaporean English and Chinese version of the EQ-5D
questionnaire was administered. The Singaporean English
EQ-5D differs from the original English version only in the VAS
instructions [18,22]. The Singaporean Chinese EQ-5D had
earlier been adapted for use in Singapore, following the EuroQol
Group’s cultural adaptation guidelines [23]. Measurement
equivalence of the two language versions had been conﬁrmed in
previous studies [18,20]. The EQ-5D contains ﬁve classiﬁers
(mobility, self-care, usual activities, pain/discomfort, anxiety/
depression), plus a VAS of overall health status. At the moment,
there is no Singaporean scoring function to convert the classiﬁers
to a utility index, although the authors are conducting a study to
develop this. The EQ-5D utility index was calculated by using the
algorithm from a Japanese study [6], which is the only Asian
EQ-5D value set to the best of our knowledge. As a sensitivity
analysis, an algorithm from the UK study of Doland was also
employed [5]. Both the Japanese and UK algorithms indicate
societal preferences, not preferences of patients. In both algo-
rithms, a respondent reporting full health (no problem in all ﬁve
domains) has a utility value of one. A subtraction is made for 1)
having at least one moderate or severe problem; 2) each moder-
ate or severe problem in the ﬁve domains; and 3) having at least
one severe problem. The two algorithms differ in the amount of
subtraction to make.
The ECOG performance status is known to be a strong
predictor of quality of life in cancer patients and is an important
concern in cancer care [24]. It can be self-administered [25].
ECOG grade 0 refers to a status “Fully active, able to carry on all
pre-disease performance without restriction”; grade 3 refers to
“Capable of only limited self-care, conﬁned to bed or chair more
than 50% of waking hours.” Grades 1 and 2 represent interme-
diate performance status. No respondents had ECOG grade 4
(Completely disabled). In the classiﬁcation of tumor sites, those
with prevalence smaller than 3% in this sample were combined
and labeled as “others.”
Statistical Analysis
The baseline survey data were used to develop the mapping
function. The EQ-5D utility index was regressed upon the
FACT–G total score or its GP, GE, GS, and GF scores. Previous
studies have suggested that because of the ceiling effect in
EQ-5D, regression methods that take into account right censor-
ing such as Tobit and censored least absolute deviations (CLAD)
methods are preferred to the ordinary least squares (OLS)
method [8,9]. Because the Tobit method is sensitive to assump-
tions of normality and homoscedasticity, the CLAD is a logical
choice [8]. We performed both CLAD and OLS for comparison
purposes. The Wald test was used to assess the statistical signiﬁ-
cance of predictors and interaction between predictors and ques-
tionnaire language. The ECOG performance score was used as a
criterion of validity to examine and compare the performance of
the observed and predicted EQ-5D utility values. Goodness-of-ﬁt
is further examined by R2, mean absolute deviation, and graphi-
cal assessment of residuals. Because OLS minimizes the R2
whereas CLAD minimizes the sum of absolute deviation, one
should bear in mind that the R2s is an index that tends to favor
the OLS, and vice versa.
We then used the follow-up data to validate the ﬁndings from
the baseline data. The signed-rank test was used to assess the
difference between observed and each of the two regression-
based predicted EQ-5D utility index values. In the analysis of
follow-up data, it was also used to assess the difference in the
predicted values based on mapping function developed from
baseline data and those based on mapping function developed
from the follow-up data. Student’s t-test was used to obtain mean
values and their 95% conﬁdence intervals. All statistical analyses
were performed in Stata version 10 (StatCrop, College Station,
TX). CLAD models were estimated by using a Stata macro [26].
Results
Descriptive Summary
Five hundred seventy-two ethnic Chinese patients who self-
administered the questionnaires were eligible in the analyses,
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among whom, 257 (44.9%) chose to answer a Chinese question-
naire. Ten patients were excluded because of missing FACT–G
values beyond imputation by the half-rule. Four patients were
excluded because of missing EQ-5D utility scores. As such, a
total of 558 patients, of whom 250 used the Chinese language,
were available for analysis.
Table 1 shows the mean age and the percentage distribution of
characteristics of the participants. The participants were hetero-
geneous in terms of type of tumor and performance status. About
half of them were receiving chemotherapy or radiotherapy.
Table 2 describes the distribution of the FACT–G scores and
EQ-5D utility index values. The mean FACT–G total score was
81.1. GE, GS, and GF reached the ﬂoor score (score zero), but the
GP and the total score did not. All the FACT–G scores reached
their ceiling levels (24 for GE, 28 for the other three domain
scales, and 108 for the total score). The EQ-5D utility index
based on the Japanese and UK algorithms were highly correlated
(Spearman’s correlation = 0.99). They gave similar mean and
median values, and both reached the ceiling level (value = 1) but
not the ﬂoor.
Regression and Prediction
Table 3 shows the regression analysis results based on the Japa-
nese algorithm. OLS regression of the EQ-5D utility index using
the FACT–G total score as the predictor gave an R2 of 0.345 and
mean absolute deviation of 0.106 (model I). Using all four
domain scores as the predictors gave an R2 of 0.451 and mean
absolute deviation of 0.097 (model II). GS, however, was not
statistically signiﬁcantly associated with EQ-5D utility index
(P = 0.467). Furthermore, the negative (-0.001) regression coef-
ﬁcient did not make sense. Model III dropped GS from the
regression equation. The R2 and mean absolute deviation were
practically unchanged. Table 3 also shows the CLAD regression
results. Model III, which used GP, GE, and GF as predictors of
utility values, gave a ﬁt not worse than models I and II did. The
R2 values were lower than those of the OLS models, e.g., 0.450
versus 0.417 for model III, but the mean absolute deviations were
also smaller, e.g., 0.097 versus 0.095 for model III.
Both in OLS and CLAD models, there was no signiﬁcant
interaction between language version and GP, GE, and GF (each
P > 0.10).
Table 4 describes the distributions of the observed (Japanese
algorithm) and two predicted EQ-5D utility indices. A signed-
rank test showed no statistically signiﬁcant differences between
the distribution of the observed and the OLS predicted values
(P = 0.788) or the CALD predicted values (P = 0.104). Although
the mean and median predicted scores based on OLS followed
the observed mean and median more closely than those based
on CLAD, the spread of the OLS predicted score was limited:
The standard deviation (SD) was only about two-thirds of the
observed SD, and the minimum and maximum scores thus calcu-
lated were 0.459 and 0.951, respectively. In contrast, the CLAD
prediction gave an SD,minimum, 10th percentile, 90th percentile,
and maximum closer to the observed values. The maximum was
0.999, which was practically reaching the full health level which is
scored at one.
The left-hand side of Table 5 describes the mean observed
(Japanese algorithm) and predicted utility values by ECOG per-
formance status in the baseline survey. The OLS prediction
tended to underestimate EQ-5D utility index in the group with
ECOG score 0 (P = 0.002) and overestimate in the group with
ECOG score 2 (P = 0.001). The CLAD prediction followed the
group-speciﬁc means more closely, although it overestimated the
mean by 0.019 in the group with ECOG score 2 (P = 0.015).
Assuming a linear trend, the observed EQ-5D utility index
decreased by 0.094 per grade, which was worse on the ECOG
scale. The corresponding ﬁgures for OLS- and CLAD-based
utility values were 0.067 and 0.082.
Validation
We used the follow-up data to validate ﬁndings from the baseline
data. Three hundred sixty patients returned the follow-up ques-
tionnaire (65%). The mean changes (95% CI) in FACT–G total
and EQ-5D utility scores from baseline to follow-up were -2.0
Table 1 Characteristics of patients completing English or Chinese
questionnaires (n = 558)
Characteristics % or mean*
Age (years) 49.3
Gender
Male 37.1
ECOG performance
0 32.8
1 40.3
2 23.5
3 3.4
On chemo/radiotherapy
Yes 54.7
Tumor site
Breast 37.1
Head & neck (inc. nasopharyngeal cancer) 18.6
Colorectal 10.9
Lung 6.1
Gynecological 6.1
Lymphoma 4.1
Prostate 3.1
Others 14.0
Questionnaire language
English 55.2
*Mean for age and % for categorical variables.
ECOG, Eastern Cooperative Oncology Group.
Table 2 Distribution of FACT–G and EQ-5D scores
Scores Mean Min Median Max % at ﬂoor % at ceiling
FACT–G
Physical 21.9 3.0 23.0 28.0 0.0 15.1
Emotional 18.2 0.0 19.0 24.0 0.2 9.7
Social 21.7 0.0 23.0 28.0 1.1 12.2
Functional 19.3 0.0 20.0 28.0 0.1 12.2
Total 81.1 18.0 83.0 108.0 0.0 1.4
EQ-5D utility index
Japanese value set 0.80 0.25 0.77 1.00 0.0 33.3
UK value set 0.81 -0.13 0.80 1.00 0.0 33.3
FACT–G, Functional Assessment of Cancer Therapy–General.
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(-3.2 to -0.8) and -0.004 (-0.017 to 0.009), respectively. Using
the follow-up data, we again found that the regression predic-
tions based on GP, GE, and GF were better than those based on
the FACT–G total scores in terms of R2 and absolute deviation,
the GS scale was not signiﬁcantly associated with the utility
index, and the GP, GE, and GF scales did not interact with
questionnaire language in making the prediction (details not
shown). Furthermore, the regression coefﬁcients estimated using
the validation data were comparable to those from the baseline.
For example, in the CLAD model III, the intercept (95% CI) was
0.244 (0.171 to 0.316) and the coefﬁcients for GP, GE, and GF
were 0.013 (0.009 to 0.017), 0.008 (0.004 to 0.012), and 0.008
(0.005 to 0.011), respectively.
In the validation data, the observed mean EQ-5D utility index
value was 0.808. The mean of the predicted values based on OLS
and CLAD were 0.774 and 0.803 (P < 0.001 and P = 0.281,
respectively, in signed-rank tests against observed values).
The right-hand side of Table 5 shows the analysis in relation
to ECOG performance status. The differences between mean
observed and CLAD predicted utility values ranged from 0.003
(ECOG 1) to 0.017 (ECOG 0) in the four groups. The CLAD and
the observed EQ-5D values had more similar gradients in rela-
tion to ECOG, with estimated linear trends of 0.129 and 0.123,
respectively, per grade worsening in ECOG, than in the baseline
survey.
Figure 1 shows the residuals calculated for OLS and CLAD
model III in the validation data. Two features are clearly visible.
First, at the individual level, the degree of variability in the
residuals was substantial. The mean, ﬁrst quartile, median, and
third quartile of the absolute deviation were, respectively, 0.083,
0.030, 0.067, and 0.117. Second, there was a trend in the residu-
als. At high values of observed EQ-5D utility index, there was a
tendency for both regression methods to underestimate, whereas
at low values, the tendency was to overestimate. Also, the pre-
diction using CLAD was more accurate than the prediction
by OLS.
Using the UK algorithm gave similar results (details not
shown).
Discussion
A utility index is important in the studies of cost-utility and
quality-adjusted survival time. Presently, most cancer-speciﬁc
HRQoL measures do not feature such an interpretation. The
Functional Assessment of Chronic Illness Therapy measurement
system is an important set of measurement tools in oncology
care and research. Recently, several studies have attempted to
provide a utility index for the FACT–G [16], FACT-L [12,13],
and FACT-P [11]. The methodological issues in using VAS to
map the FACT-L to a utility index have been controversial
Table 3 Regression of EQ-5D utility index upon FACT–G scores by ordinary least squares (OLS) and censored least absolute deviation (CLAD)
Scores
OLS CLAD
Model I Model II Model III Model I Model II Model III
Physical 0.013* 0.013* 0.014* 0.014*
Emotional 0.005* 0.004* 0.006** 0.006*
Social -0.001 -0.002
Functional 0.005* 0.005* 0.009* 0.008*
FACT–G Total 0.006* 0.007*
Constant 0.350* 0.352* 0.341* 0.229* 0.254* 0.238*
R2 0.345 0.451 0.450 0.317 0.409 0.417
Mean absolute deviation 0.106 0.097 0.097 0.104 0.095 0.095
*P < 0.001; **P < 0.01.
FACT–G, Functional Assessment of Cancer Therapy–General.
Table 4 Descriptive summary of utility indices derived from observed EQ-5D data and regression models
Utility index Mean SD Minimum P10 Median P90 Maximum
Observed 0.803 0.156 0.246 0.628 0.769 1.000 1.000
OLS Model III 0.803 0.105 0.459 0.659 0.813 0.926 0.951
CLAD model III 0.811 0.130 0.393 0.633 0.822 0.969 0.999
CLAD, censored least absolute deviation; OLS, ordinary least squares; SD, standard deviation; P10 and P90, 10th and 90th percentiles.
Table 5 Utility values by ECOG performance scores at baseline and follow-up survey
ECOG
Baseline Follow-up
Observed OLS Model III CLAD Model III Observed OLS Model III CLAD Model III
0† 0.899 0.869* 0.8921 0.921 0.853* 0.904**
1 0.791 0.797 0.803 0.773 0.754** 0.776
2 0.718 0.744* 0.737** 0.678 0.668 0.666
3 0.596 0.644 0.616 0.530 0.560 0.526
Linear trend‡ -0.094* -0.067* -0.082* -0.129* -0.095* -0.123*
*P < 0.01 and **P < 0.05.
†Signed-rank test for difference between observed and each predicted utility values within each ECOG category.
‡Test for linear trend in (observed or predicted) utility values across ECOG categories.
CLAD, censored least absolute deviation; ECOG, Eastern Cooperative Oncology Group; OLS, ordinary least squares.
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[14,15]. Directly eliciting time trade-off values from cancer
patients for the FACT–G has been successful at the group level,
but the accuracy is limited at the individual level [16]. A func-
tion for converting the FACT-P to the EQ-5D utility index has
been developed [11], but the absolute deviation is substantial
and further information on its performance at the individual
level is needed.
Following previous researchers’ recommendations, we have
estimated and compared OLS and CLAD regression models. In
our opinion, the solution given by CLAD more closely describes
the variation of health utilities in the present sample. The FACT
Social/Family scale was not associated with EQ-5D utility index.
This is not surprising because the EQ-5D does not include a
classiﬁer on this aspect of quality of life. Furthermore, items on
social aspects of quality of life tend to differ in focus even among
cancer-speciﬁc HRQoL measures [24]. This highlights the need
of future research to consider further the utility value of social
aspects of HRQoL and how to measure it. In both our study and
the previous study of the FACT-P [11], the regression coefﬁcient
for the Social/Family scale was negative. It is not sensible to
expect that a better social well-being would reduce one’s health
utility. Unlike the previous study, we have excluded the GS scale
from the mapping function. Data from a follow-up survey con-
ﬁrmed and validated the ﬁndings based on the baseline survey.
The analyses were not sensitive to the choice between Japanese
and UK scoring functions.
At the group level, the CLAD regression equation
EQ- D utility index GP
GE GF
5 0 238 0 014
0 006 0 008
= + × +
× + ×
. .
. . (1)
was successful in predicting the observed EQ-5D utility index
values. This reﬂects societal preferences as the Japanese and UK
algorithms employed in this mapping exercise were both based
on population value sets. The mean and median absolute devia-
tions were smaller than those in the previous study mapping
the FACT-P to the EQ-5D [11]. In the development and valida-
tion samples, the overall differences in mean between the CLAD-
based and the observed utility index values were 0.008 and
0.005, respectively. They are far smaller than the previously
suggested deﬁnitions of a minimal clinically important difference
(MCID; 0.03 to 0.05) [16,18]. The equation also accurately
provided estimates of the mean utility index values in patients
with different performance status in the validation sample. The
difference within each ECOG group was again smaller than the
strict deﬁnition of MCID (0.03). The trend in CLAD-based
utility values in relation to ECOG was very similar to that based
on the observed EQ-5D utility values (-0.123 vs. -0.129), sug-
gesting their equivalence also in studies of association.
The equation is easy to use and allows clinicians and
researchers who only have FACT–G data to obtain a health
utility value. The predictors did not interact with language
version. Hence, a single equation can be applied to both the
English and Chinese versions of the FACT–G. The English and
Chinese languages are two of the world’s most spoken languages
[17]. The ﬁndings here will be useful to many people and cancer
centers.
At the individual level, however, graphical examination of
residuals showed a considerable level of inaccuracy, as well as a
systematic pattern of underestimation in those with large and
overestimation among those with small utility values. This
pattern is similar to that found in the time trade-off study of
Dobrez et al. [16]. As such, we would like to repeat the cau-
tionary note that the use of mapped utility index values may not
be appropriate for application at the individual level [10,16].
Other approaches to obtain health utilities in individual cancer
patients need further research. Cost-utility studies, however,
typically use group means instead of individual-level data [16].
Therefore, the present ﬁndings remain useful.
In conclusion, our study offers an equation for calculating a
health utility index at the group level based on the English or
Chinese versions of the FACT–G. This should add to the arma-
mentarium of measures for use in cost-utility and quality-
adjusted survival time studies in cancer research.
The study was supported by a research grant from the National Medical
Research Council, Singapore (# NMRC/0822/2004), who played no role
in the design, analysis, or reporting of this study.
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